PT  - JOURNAL ARTICLE
AU  - Schumacher, Laurence
AU  - Dhif, Yassine
AU  - Bonnabry, Pascal
AU  - Widmer, Nicolas
TI  - Management of the Covid-19 Health Crisis: A Survey in Swiss Hospital Pharmacies
AID  - 10.1101/2020.12.08.20237339
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2020.12.08.20237339
4099  - http://medrxiv.org/content/early/2023/03/17/2020.12.08.20237339.short
4100  - http://medrxiv.org/content/early/2023/03/17/2020.12.08.20237339.full
AB  - Background The COVID-19 pandemic has put a lot of strain on health systems since 2020. A review of the Swiss hospital pharmacies responses during the first wave was performed to improve the quality of the pharmaceutical management of future health crises.Methods An electronic survey was sent to all head of hospital pharmacies in Switzerland. The questionnaire was organized into eleven clusters of questions and covered many topics regarding the management of the first wave of COVID-19. Data collection was conducted from May to June, 2020.Results Analyses were performed with 43 responses (66%) out of 65 questionnaires sent (at least one answer per questionnaire). 41% (17/41) of pharmacies had existing standard operating procedures or pandemic plans and 95% of them (39/41) created a steering committee to manage the crisis. 67% (29/43) created new activities to respond to the specific needs of the crisis. 67% (26/39) created new drug lists for: COVID-19-specific treatments (85% of pharmacies; 22/26), sedatives (81%; 21/26), anaesthetics (77%; 20/26) and antibiotics (73%; 19/26). Drug availability in COVID-19 wards was managed by increasing existing stocks (54% of pharmacies; 22/41) and creating extra storage space (51%; 21/41). Two drugs generated the most concern about shortages: propofol (49% of pharmacies; 19/39) and midazolam (44%; 17/39). Remdesivir stocks even ran out in 26% of pharmacies (10/39). Specific new documents were drafted to respond to medical needs with regards to drug administration (28% of pharmacies; 12/43), drug preparation (28%; 12/43) and treatment choices (23%; 10/43).Conclusions Swiss hospital pharmacies encountered many challenges related to the COVID-19 crisis and had to find solutions quickly, effectively and safely. The survey highlights the key role played by Hospital Pharmacy’s in many aspects during the pandemic by providing logistical and clinical support to medical and care teams. The lessons and experiences outlined could be used to improve the quality of the preparation for similar future events.KEY POINTS▸ The COVID-19 pandemic generated unprecedented global demand for specific drugs, hand sanitizer solution, and other therapeutic products, particularly in critical care settings, highlighting the essential role of hospital pharmacists in such crises.▸ Key COVID-19 responses at the hospital pharmacy level included staff flexibility with regards to changes in roles and procedures, communication, teamwork and solidarity, and the need to prepare business continuity plans and management dashboards ▸ Managing and facing complex pandemic response reveals the importance of involving hospital pharmacists in pandemic response steering committees at many levels. The lived experiences during the pandemic could have been reviewed and evaluated to raise awareness and guide future policy responses for when the next crisis occurs.Competing Interest StatementThe authors have declared no potential conflicts of interest.Funding StatementThis study was funded by the Swiss Federal Department of Defence, Civil Protection and Sport, through the Centre of Competence for Military and Disaster Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research protocol, which did not imply patient data collection, has been presented to the Cantonal Research Ethics Committee Geneva, which waived an ethical oversight.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data of the survey would be provided upon requestCOVID-19Coronavirus disease 2019EpidASwiss Federal Act on EpidemicsFFrench-speaking region of SwitzerlandGGerman-speaking region of SwitzerlandGSASASwiss Society of Public Health Administration and Hospital PharmacistsIItalian-speaking region of SwitzerlandICUIntensive Care UnitMERS-CoVMiddle East respiratory syndrome coronavirusRRomansh-speaking region of SwitzerlandSARS-CoV-1Severe acute respiratory syndrome coronavirus 1SARS-CoV-2Severe acute respiratory syndrome coronavirus 2SwissmedicSwiss Agency for Therapeutic ProductsWHOWorld Health Organisation